

Media Contact:

Organon Canada
Media_Canada@Organon.com
1-450-366-1740

Organon Canada announces availability of the JADA[®] System, a medical device intended to control and treat postpartum hemorrhage (PPH)

JADA[®] is a novel System authorized in Canada to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.¹

PPH is the leading cause of maternal mortality worldwide and accounts for about 25% of all maternal deaths.²

KIRKLAND, QC — September 30, 2024 – Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, is announcing the availability of the JADA[®] System to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.¹

Postpartum hemorrhage (PPH) is defined as blood loss of 500 mL or more following vaginal delivery, or 1,000 mL or more following cesarean section.³

Globally, PPH represents the leading cause of maternal deaths.² In Canada, PPH increased by 22% from 2003 to 2010.⁴ Despite being one of the more common complications of birth,⁵ there has been little progress in the space.^{6,7}

“The availability of the JADA[®] System represents a new treatment option for women in Canada in the management of post-partum hemorrhage, the leading cause of maternal mortality worldwide,² and marks an important milestone in our company’s ethos to be Here for Her Health,” said Michael Casia, President and Managing Director, Organon Canada.

In recognition of the growing need for action to improve PPH prevention and care, the World Health Organization (WHO) is working alongside key stakeholders in the public and private sector, including Organon, to tackle this issue through research, advocacy and progress with the first global coalition focused on PPH.⁷

The JADA[®] System became part of the Organon women’s health portfolio in June 2021, as part of the company’s first acquisition, continuing to build upon our leadership in women’s health. The JADA[®] System was approved for use in Canada in February 2024.

About the JADA® System¹

JADA is designed to apply low level vacuum to encourage normal contraction of the uterus to provide control and treatment of abnormal uterine bleeding or hemorrhage after childbirth. Please refer to the Jada System Instructions for Use for indications, warnings, precautions, and contraindications available at: <https://www.organon.com/canada-en/jada-instructions-for-use>.

About Organon

Organon is an independent global healthcare company with a strategy to help improve the health of women throughout their lives. Organon's diverse portfolio offers more than 60 medicines and products in women's health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon's current products, the company invests in innovative solutions and research to drive future growth opportunities in women's health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical partners and innovators looking to commercialize their products by leveraging its scale and agile presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit www.organon.ca and connect with us on [LinkedIn](#).

###

References: **1.** Organon Canada, JADA SYSTEM Instructions for Use. 2024. **2.** McLintock C. Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management. *Hematology Am Soc Hematol Educ Program*. 2020 Dec 4;2020(1):542-546. doi: 10.1182/hematology.2020000139. PMID: 33275708; PMCID: PMC7727513. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727513/>. **3.** Robinson D, Basso M, Chan C, Duckitt K, Lett R. Guideline No. 431: Postpartum Hemorrhage and Hemorrhagic Shock. *J Obstet Gynaecol Can*. 2022 Dec;44(12):1293-1310.e1. doi: 10.1016/j.jogc.2022.10.002. **4.** Mehrabadi A, Liu S, Bartholomew S, et al; Maternal Health Study Group of the Canadian Perinatal Surveillance System (Public Health Agency of Canada). Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage in Canada from 2003 to 2010. *J Obstet Gynaecol Can*. 2014 Jan;36(1):21-33. doi: 10.1016/S1701-2163(15)30680-0. **5.** Maternal mortality. *Who.int*. Accessed March 10, 2024. <https://www.who.int/news-room/fact-sheets/detail/maternal-mortality>. **6.** UNFPA, Maternal Health, May 2022, available: <https://www.unfpa.org/maternal-health> [Accessed: September 2024]. **7.** A roadmap to combat postpartum haemorrhage between 2023 and 2030. (2023, October 11). *Who.int*; World Health Organization. <https://cdn.who.int/media/docs/default-source/reproductive-health/maternal-health/pph-roadmap.pdf>.